Related Articles
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing
IDH1‑R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR
Associations between SOX2 and miR‑200b expression with the clinicopathological characteristics and prognosis of patients with glioma